10-Q: MIRA Pharmaceuticals Q3 2025: SKNY Acquisition Boosts Assets

MIRA Pharmaceuticals reports a significant increase in assets and equity driven by the SKNY acquisition, while continuing clinical trials for its drug candidates.

Summary

• Acquired SKNY Pharmaceuticals, a related party, on September 29, 2025, expanding the drug pipeline with SKNY-1, a preclinical-stage oral therapeutic.
• The SKNY acquisition included 3,521,127 shares of Telomir Pharmaceuticals (TELO) common stock, valued at $4,718,310 on the acquisition date, which increased to $4,894,366 by September 30, 2025.
• Issued 19,755,738 new MIRA common shares to SKNY shareholders, valued at $26,275,132, resulting in a $21,556,821 deemed dividend.
• Reported a net loss attributable to common shareholders of $(26,015,985) for the nine months ended September 30, 2025, significantly impacted by the deemed dividend.
• Cash balance as of September 30, 2025, was $2,641,539, a decrease from $2,832,931 at December 31, 2024.
• Total assets increased to $7,633,280 as of September 30, 2025, from $2,923,099 at December 31, 2024, primarily due to the TELO shares.
• Stockholders' equity rose to $7,549,354 as of September 30, 2025, from $2,199,750 at December 31, 2024, successfully regaining Nasdaq compliance.
• Research and development expenses decreased to $1,223,240 for the nine months ended September 30, 2025, from $2,444,134 in the prior year period.
• General and administrative expenses increased to $3,445,045 for the nine months ended September 30, 2025, from $3,136,393 in the prior year period.
• The FDA cleared the Investigational New Drug (IND) application for Ketamir-2, enabling U.S.-based clinical trials.
• Completed the Single Ascending Dose (SAD) portion of the Phase 1 clinical trial for oral Ketamir-2, demonstrating a favorable safety and tolerability profile.
• Initiated the Multiple Ascending Dose (MAD) portion of the Phase 1 clinical trial for Ketamir-2 and selected chemotherapy-induced peripheral neuropathy (CIPN) as the lead indication for a planned Phase 2a study in the first half of 2026.
• Preclinical studies for MIRA-55 and topical Ketamir-2 showed positive analgesic and anti-inflammatory effects.
• The U.S. DEA concluded that Ketamir-2 and MIRA-55 are not controlled substances.

Sentiment

Score: 5

Explanation: The filing presents a mixed bag. While there's significant clinical progress, a strategic acquisition, and successful Nasdaq compliance, the substantial net loss attributable to common shareholders (due to the deemed dividend) and the explicit 'going concern' warning highlight ongoing financial fragility and reliance on future capital raises. The reduction in R&D expenses could be seen as a positive for cash burn, but also raises questions about development pace.

Positives

• Successful acquisition of SKNY Pharmaceuticals, expanding the drug pipeline with SKNY-1, a preclinical-stage oral therapeutic.
• Significant increase in total assets to $7,633,280 as of September 30, 2025, largely due to the acquisition of Telomir Pharmaceuticals shares.
• Stockholders' equity increased to $7,549,354, successfully regaining compliance with Nasdaq's minimum equity requirement of $2.5 million.
• FDA clearance of the IND application for Ketamir-2 allows for U.S.-based clinical trials.
• Favorable safety and tolerability profile observed in the completed SAD portion of the Phase 1 clinical trial for Ketamir-2.
• Initiation of the MAD portion of the Phase 1 trial for Ketamir-2 and selection of CIPN for Phase 2a, indicating clinical progress.
• Positive preclinical results for MIRA-55 and topical Ketamir-2, demonstrating analgesic and anti-inflammatory effects.
• The U.S. DEA concluded that Ketamir-2 and MIRA-55 are not controlled substances, potentially streamlining development and commercialization.
• Reduced cash used in operating activities for the nine months ended September 30, 2025, compared to the prior year, at $(3,526,632) versus $(3,755,576).

Negatives

• Reported a substantial net loss attributable to common shareholders of $(26,015,985) for the nine months ended September 30, 2025, primarily due to a $21,556,821 deemed dividend related to the SKNY acquisition.
• Basic and diluted loss per share significantly worsened to $(1.45) for the nine months ended September 30, 2025, compared to $(0.36) in the prior year.
• The company continues to operate at a net loss and has historically had no revenues.
• Cash balance decreased to $2,641,539 as of September 30, 2025, from $2,832,931 at December 31, 2024.
• Substantial doubt exists about the company's ability to continue as a going concern for the next 12 months without additional external funding.
• General and administrative expenses increased to $3,445,045 for the nine months ended September 30, 2025, primarily due to higher stock-based compensation.
• The company relies heavily on related parties for funding and license agreements.

Risks

• Reliance on related parties for potential funding and licenses for Ketamir-2, MIRA-55, and SKNY-1.
• Ability to obtain and maintain regulatory approval of product candidates.
• Ability to successfully commercialize and market product candidates, if approved.
• Ability to contract with third-party suppliers, manufacturers, and other service providers and their ability to perform adequately.
• The potential market size, opportunity, and growth potential for product candidates, if approved.
• Ability to obtain additional funding for operations and development activities, with no assurance that any fundraising will be achieved on commercially reasonable terms, if at all.
• The accuracy of estimates regarding expenses, capital requirements, and needs for additional financing.
• The initiation, timing, progress, and results of clinical studies and clinical trials, and research and development programs.
• The timing of anticipated regulatory filings and the timing of availability of data from clinical trials.
• Future expenses, capital requirements, need for additional financing, and the period over which existing cash and cash equivalents will be sufficient to fund operating expenses and capital expenditure requirements.
• Ability to retain the continued service of key professionals and to identify, hire, and retain additional qualified professionals.
• Ability to advance product candidates into, and successfully complete, clinical trials, and to recruit and enroll suitable patients.
• The timing or likelihood of the accomplishment of various scientific, clinical, regulatory, and other product development objectives.
• The pricing and reimbursement of product candidates, if approved, and the rate and degree of market acceptance.
• The implementation of the business model and strategic plans for the business, product candidates, and technology.
• The scope of protection the company is able to establish and maintain for intellectual property rights covering product candidates and technology.
• Developments relating to competitors and the industry.
• The development of major public health concerns and the future impact of such concerns on clinical trials, business operations, and funding requirements.
• The company has insufficient cash and cash equivalents to support operations for at least the 12 months following the date the financial statements are issued, raising substantial doubt about its ability to continue as a going concern.
• Risk of delisting from the Nasdaq Capital Market if the company fails to maintain compliance with Nasdaq's listing requirements.

Future Outlook

The company expects to continue generating losses in the foreseeable future and requires additional financing to fund operations, complete clinical development, and commercially launch product candidates. It anticipates being able to fund operations through the third quarter of 2026 using existing cash and proceeds from its At-the-Market (ATM) equity program. A Phase 2a study for Ketamir-2 in chemotherapy-induced peripheral neuropathy (CIPN) is planned to begin in the first half of 2026, subject to regulatory feedback and site readiness. The company plans to seek additional capital through public equity offerings and strategic transactions.

Management Comments

• Management cannot provide assurance that the Company will ultimately achieve profitable operations or become cash flow positive or raise additional debt and/or equity capital.
• If the Company is unable to raise additional capital or secure additional lending in the near future, management expects that the Company will need to curtail its operations.
• We expect to be able to fund operations through the third quarter of 2026, with the issuance of common stock under our shelf registration statement.
• We will require additional financing to fund our operations, to continue and complete clinical and clinical development activities and to commercially develop and ultimately launch our product candidates.

Industry Context

MIRA Pharmaceuticals operates in the highly competitive and capital-intensive clinical-stage pharmaceutical development sector, focusing on neuroscience and metabolic-behavioral disorders. The acquisition of SKNY Pharmaceuticals and its SKNY-1 candidate, which aims to modulate CB1, CB2, and MAO-B pathways without the psychiatric side effects of earlier CB1-targeting drugs, positions MIRA to address a significant unmet need in obesity and addiction, a market segment that has seen challenges with previous drug candidates. The progress of Ketamir-2 through Phase 1 trials and the planned Phase 2a for chemotherapy-induced peripheral neuropathy (CIPN) places MIRA among numerous biotechs vying for breakthroughs in pain management and neuropsychiatric conditions. The DEA's non-controlled substance classification for Ketamir-2 and MIRA-55 could offer a competitive advantage by simplifying regulatory pathways compared to compounds with controlled substance designations. The company's reliance on ATM offerings for funding is a common strategy for early-stage biotechs, but also highlights the ongoing need for capital in this industry.

Comparison to Industry Standards

• The company's preclinical and Phase 1 trial progress for Ketamir-2 and MIRA-55 is consistent with the typical development timelines for novel drug candidates in the pharmaceutical industry.
• The successful completion of the SAD portion of the Phase 1 trial for Ketamir-2, demonstrating a favorable safety and tolerability profile, aligns with expected early-stage clinical trial outcomes for promising drug candidates.
• The preclinical results for SKNY-1, showing reductions in food consumption, body-weight gain, and nicotine-seeking behavior in zebrafish models, and lack of anxiety-related responses in rodent models, suggest a potentially improved safety profile compared to earlier CB1-targeting drugs like Rimonabant (Sanofi-Aventis), which faced withdrawal due to psychiatric side effects.
• The company's cash burn rate and reliance on equity financing, particularly through ATM offerings, are standard for clinical-stage biotechnology companies that have no revenue and significant research and development expenses.
• The Nasdaq compliance issue and subsequent resolution through increased stockholders' equity is a common challenge for smaller reporting companies, and the company's ability to regain compliance demonstrates a proactive approach to maintaining listing standards.

Corporate Governance

Legal Proceedings

• No legal proceedings, government actions, administrative actions, investigations, or claims are pending that are expected to have a material adverse effect on the business and financial condition.
• The company anticipates expending significant financial and managerial resources in the future to defend its intellectual property rights and against claims of infringement by third parties.

Related Party Transactions

• Exclusive license agreement with MIRALOGX, LLC (same founder as MIRA, related to largest shareholder) for Ketamir-2, involving a one-time $0.1 million payment and 8% quarterly royalty on net sales and other revenue.
• Acquisition of SKNY Pharmaceuticals, Inc. (a related party due to common shareholders and licensor) on September 29, 2025.
• SKNY acquisition included the SKNY License from MIRALOGX, obligating MIRA to pay an 8% royalty on net sales of SKNY-1, with a minimum annual royalty of $250,000.
• SKNY's largest shareholder contributed 3,521,127 shares of Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a related party through common ownership, officers, and directors, as part of the SKNY acquisition consideration.
• Amounts due from MIRALOGX totaled $0.04 million as of September 30, 2025, for accounts payable paid on its behalf (research and development payables).

Stakeholder Impact

• Shareholders face potential for dilution from ongoing At-the-Market (ATM) equity offerings and shares issued for the SKNY acquisition (19,755,738 new shares). The deemed dividend of $21,556,821 negatively impacted net loss attributable to common shareholders and loss per share. However, the increase in stockholders' equity to $7.5 million helped regain Nasdaq compliance, reducing delisting risk. Clinical progress and pipeline expansion offer long-term value potential, but the 'going concern' warning poses significant risk.
• Employees/Management: Stock-based compensation remains a significant component of expenses. CEO Erez Aminov received a repricing of options and an RSU award under the EICP, aligning incentives with company performance.
• Customers (future): The expanded pipeline with Ketamir-2, MIRA-55, and SKNY-1 aims to address unmet medical needs in neuropathic pain, anxiety, cognitive decline, inflammatory pain, obesity, and nicotine addiction, potentially offering new therapeutic options.
• Creditors: The 'going concern' warning indicates increased risk for creditors, as the company's ability to meet obligations is dependent on future capital raises.
• Regulatory Authorities: FDA clearance of Ketamir-2 IND and DEA's non-controlled substance classification are positive signals for regulatory pathways.

Next Steps

• Continue the Multiple Ascending Dose (MAD) portion of the Phase 1 clinical trial for Ketamir-2.
• Initiate a Phase 2a study for Ketamir-2 in chemotherapy-induced peripheral neuropathy (CIPN) in the first half of 2026, subject to regulatory feedback and site readiness.
• Continue preclinical development of MIRA-55 toward IND-enabling studies.
• Continue preclinical development of SKNY-1 in models of metabolic and behavioral modulation.
• Seek additional capital through public equity offerings (e.g., ATM Agreement) and strategic transactions (e.g., alliances, drug product collaborations) to fund operations and future clinical trials.
• Monitor and maintain compliance with Nasdaq's listing requirements.
• Potentially curtail operations if unable to raise additional capital.

Key Dates

Recommendation

While MIRA Pharmaceuticals has made significant clinical progress with its drug candidates (Ketamir-2, MIRA-55, SKNY-1) and successfully regained Nasdaq compliance, the substantial net loss attributable to common shareholders (due to the deemed dividend) and the explicit 'going concern' warning indicate ongoing financial challenges and high operational risk. The company's reliance on continuous capital raises through ATM offerings suggests a need for further dilution. The strategic acquisition of SKNY and positive preclinical data are encouraging, but the company remains pre-revenue and highly speculative. A 'hold' recommendation is appropriate for existing investors to monitor clinical milestones and capital management, while new investors should exercise extreme caution given the significant risks and the need for substantial future funding.

Keywords

Pharmaceutical development, Clinical-stage, Neuroscience, Metabolic-behavioral disorders, Ketamir-2, MIRA-55, SKNY-1, Neuropathic pain, Inflammatory pain, Neuropsychiatric disorders, Obesity, Nicotine addiction, Phase 1 clinical trial, IND clearance, SEC filing, 10-Q, Biotechnology, Drug development, Nasdaq compliance, Going concern, SKNY acquisition, Telomir Pharmaceuticals